Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Developed by Novo Nordisk in the late 1990s, ipamorelin stimulates growth hormone (GH) release from somatotroph cells in the anterior pituitary gland through direct receptor activation, triggering the Gq/11-phospholipase C signalling cascade that leads to calcium-mediated exocytosis of GH-containing secretory granules
There, fatty acids are converted into energy (ATP) that cells require for their work
CJC 1295 + Ipamorelin when injected correctly can produce extremely beneficial results with minimal side effects compared to other growth hormone therapies such as synthetic HGH therapy which require daily injections and may be accompanied by more intense side effects
Synthetic Lethal Screening Identifies Compounds Activating Iron-dependent, Nonapoptotic Cell Death in Oncogenic-RAS-Harboring Cancer Cells
